Trevi Therapeutics stock (TRVI) experienced a dramatic rally on July 18, 2026, following the release of a significant market analysis for its lead drug candidate, Haduvio. The company’s share price increased by approximately 175%, climbing from a previous close of $2.10 to an intraday high of $5.78. This surge was triggered by new data projecting a total addressable market of $15 billion for Haduvio in treating chronic cough, a condition with limited approved therapies. Trading volume exceeded 45 million shares, more than 20 times the 90-day average, indicating intense institutional interest.
Context — why the Haduvio market estimate matters now
The chronic cough treatment landscape has been active since the 2024 FDA approval of Merck’s gefapixant, which itself targeted a multi-billion dollar patient population. The last comparable market-size catalyst for a neuropathic disorder drug occurred in September 2025, when Vertex Pharmaceuticals released a $10 billion sales peak estimate for its pain drug VX-548, lifting its market cap by over $15 billion in a single session. The current biotech funding environment remains selective, with the XBI Biotech ETF up 12% year-to-date but still 25% below its 2021 peak. The substantial $15 billion figure for Haduvio stands out by suggesting a patient population and pricing power exceeding prior analyst expectations, effectively repositioning Trevi from a micro-cap developer to a potential mid-cap entity.
Data — what the numbers show
Trevi Therapeutics' market capitalization increased by nearly $400 million during the trading session, reaching approximately $650 million. The $15 billion addressable market figure represents a potential revenue opportunity roughly 100 times the company's current enterprise value. This compares to Merck’s gefapixant, which analysts project to achieve peak sales of $1.5 to $2 billion. Haduvio is also under investigation for treating prurigo nodularis, a secondary indication that could expand its market potential by an estimated 20%. The stock’s volatility index spiked to 150%, reflecting extreme trader positioning. The rally pushed TRVI’s relative strength index (RSI) above 85, signaling severely overbought conditions.
| Metric | Pre-Announcement | Post-Announcement | Change |
|---|
| Share Price | $2.10 | $5.78 | +175% |
| Market Cap | ~$250M | ~$650M | +$400M |
| Trading Volume | 2.1M (avg) | 45M | +2040% |
Analysis — what it means for markets and sectors
The primary second-order effect is a positive read-through to other companies targeting neuropathic and chronic cough indications. Stocks like Bellus Health (BLCO) and Bayer, which are developing similar P2X3 receptor antagonists, saw moderate gains of 5-8% on the session. Conversely, the projected market share capture by Haduvio introduces a new competitive risk for Merck’s gefapixant franchise, potentially capping its long-term growth narrative. A key risk to the optimistic valuation is the regulatory pathway; Haduvio’s Phase 3 trial results are not expected until late 2027, leaving a significant time gap before potential commercialization. Options flow data indicates heavy call buying from hedge funds, while some long-term biotech ETFs appear to be taking profits on the surge.
Outlook — what to watch next
The next major catalyst for Trevi is the release of additional Phase 2 data for Haduvio in prurigo nodularis, expected by the end of the third quarter of 2026. The primary Phase 3 clinical trial for chronic cough, named CANAL, has a primary completion date of November 2027. Traders will monitor the $5.00 share price level as critical support; a break below could signal a rapid unwinding of short-term speculative positions. Key resistance sits near the day’s high of $5.78. Further analyst coverage initiation from major investment banks is anticipated within the next two weeks, which will provide formal revenue models and price targets.
Frequently Asked Questions
What is Haduvio and how does it work?
Haduvio (oral nalbuphine ER) is an investigational drug that acts as a kappa opioid receptor agonist and a mu opioid receptor partial antagonist. This dual mechanism targets the nervous system pathways responsible for the urge-to-cough reflex in chronic cough and the intense itch sensation in prurigo nodularis. Unlike traditional suppressants, it aims to address the underlying neurological cause of the chronic condition rather than just providing temporary symptomatic relief.
How does Trevi’s market cap compare to the projected drug sales?
The disparity between Trevi’s current market cap of approximately $650 million and the $15 billion total addressable market is significant. This discount reflects the substantial risk that the drug may not gain regulatory approval, might only capture a fraction of the market, or could face commercial challenges. For context, successful commercial-stage biotech companies often trade at 3-5x their peak sales estimates, suggesting Trevi’s valuation has room for expansion if clinical and regulatory milestones are met.
What are the main risks for investors after this price surge?
The primary risk is clinical failure; negative results from the ongoing Phase 3 trial would likely cause the stock to collapse. Additional risks include significant share dilution from future capital raises needed to fund the costly trial, potential competition from newer therapies, and the possibility that the $15 billion market estimate proves overly optimistic upon deeper analysis. The extreme volatility following the news also increases the risk of sharp pullbacks.
Bottom Line
The Haduvio market estimate fundamentally reprices Trevi Therapeutics based on a vastly expanded commercial opportunity, contingent on future clinical success.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
